Literature Review: The Long-Term Use Effect of Proton Pump Inhibitors and The Risk of Fractures

Adelia Fatharani; Indah Laily Hilmi

Authors

Adelia Fatharani Universitas Singaperbangsa Karawang
Indah Laily Hilmi Universitas Singaperbangsa Karawang

Keywords:

Proton Pump Inhibitors, long-term use, fracture

Abstract

Proton Pump Inhibitors (PPIs) are a group of drugs widely used to treat gastrointestinal disorders. Long-term use of PPIs has a risk of several side effects, one of them is fractures. The aims of this study is to examine the relationship between long-term PPIs use and the risk of fractures. The method in this literature review was literature study by searching for research article through Google Scholar and Pubmed Central by using the keywords "Proton pump inhibitors, Long-term use, Risk, Fracture". An analysis of 10 selected journals was conducted and concluded that the long-term use of PPIs has a risk of fracture.

References

B. Katzung, M. Hall, and A. Trevor, Pharmacology Examination & Board Review, 12th ed. McGraw-HillEducation, 2019.

FDA, “FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors,” 2011. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump (accessed Oct. 07, 2022).

Ó. Hálfdánarson et al., “Proton-pump inhibitors among adults: a nationwide drug-utilization study,” Therap. Adv. Gastroenterol., vol. 11, pp. 1–11, 2018, doi: 10.1177/1756284818777943.

Y. Kinoshita, N. Ishimura, and S. Ishihara, “Advantages and disadvantages of long-term proton pump inhibitor use,” J. Neurogastroenterol. Motil., vol. 24, no. 2, pp. 182–196, 2018, doi: 10.5056/jnm18001.

S. Dewi, P. W. Laksmi, A. F. Syam, E. Dewiasty, and E. Seto, “Pengaruh Penggunaan Proton Pump Inhibitor Jangka Panjang terhadap Sindrom Frailty pada Pasien Usia Lanjut,” J. Penyakit Dalam Indones., vol. 3, no. 3, p. 143, 2016, doi: 10.7454/jpdi.v3i3.115.

M. Z. Shabrina, M. Andrie, J. Farmasi, F. Kedokteran, and U. Tanjungpura, “Karakteristik Dan Penggunaan Obat Pasien Dispepsia Rawat Inap Di Rumah Sakit,” Karakteristik Dan Pengguna. Obat Pasien Dispepsia Rawat Ina. Di Rumah Sakit, vol. 4, pp. 447–456, 2022, [Online]. Available: http://ejurnal.ung.ac.id/index.php/jsscr

R. Setiyawati and D. Hastuti, “Pola Peresepan Obat Dispepsia Pada Pasien Dewasa Di Klinik Kimia Farma 275 Yogyakarta Periode Januari-April 2019,” J. Kefarmasian Akfarindo, vol. 6, no. 1, pp. 14–20, 2021, doi: 10.37089/jofar.vi0.99.

J. R. Lewis et al., “Long-term proton pump inhibitor therapy and falls and fractures in elderly women: A prospective cohort study,” J. Bone Miner. Res., vol. 29, no. 11, pp. 2489–2497, 2014, doi: 10.1002/jbmr.2279.

Y. W. Min et al., “Proton pump inhibitor use is associated with hip fracture development: A nationwide population-based cohort study,” Korean J. Intern. Med., vol. 35, no. 5, pp. 1084–1093, 2020, doi: 10.3904/kjim.2018.331.

J. H. Park et al., “Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease,” BMC Geriatr., vol. 20, no. 1, pp. 1–11, 2020, doi: 10.1186/s12877-020-01794-3.

Y. H. Wang, V. Wintzell, J. F. Ludvigsson, H. Svanström, and B. Pasternak, “Association between Proton Pump Inhibitor Use and Risk of Fracture in Children,” JAMA Pediatr., vol. 174, no. 6, pp. 543–551, 2020, doi: 10.1001/jamapediatrics.2020.0007.

J. J. Kim, E. J. Jang, J. Park, and H. S. Sohn, “Association between proton pump inhibitor use and risk of fracture: A population-based case-control study,” PLoS One, vol. 15, no. 7 July, pp. 1–13, 2020, doi: 10.1371/journal.pone.0235163.

N. Fleishman, T. Richardson, and T. Attard, “The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors,” J. Pediatr. Gastroenterol. Nutr., vol. 70, no. 6, pp. 815–819, 2020, doi: 10.1097/MPG.0000000000002690.

Y. S. Chou, H. J. Jiang, C. H. Chen, P. S. Ho, and T. C. Lee, “Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes,” Sci. Rep., vol. 10, no. 1, pp. 1–8, 2020, doi: 10.1038/s41598-020-70712-9.

M. Fusaro et al., “Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS),” J. Bone Miner. Res., vol. 34, no. 12, pp. 2238–2245, 2019, doi: 10.1002/jbmr.3842.

C. Vangala, J. Niu, C. R. Lenihan, W. E. Mitch, S. D. Navaneethan, and W. C. Winkelmayer, “Proton pump inhibitors, histamine-2 receptor antagonists, and hip fracture risk among patients on hemodialysis,” Clin. J. Am. Soc. Nephrol., vol. 13, no. 10, pp. 1534–1541, 2018, doi: 10.2215/CJN.02190218.

B. Lyu, M. R. Jorgenson, K. E. Hansen, A. Djamali, and B. C. Astor, “Proton pump inhibitors, but not H2-receptor antagonists, are associated with incident fractures among kidney transplant recipients,” Transplantation, vol. 104, no. 12, pp. 2609–2615, 2020, doi: 10.1097/TP.0000000000003178.

B. H. Tortora, G. J., & Derrickson, Principles of anatomy and physiology, Sixteenth. John Wiley & Sons, 2018.

Farapti and S. Sayogo, “Manfaat Vitamin B6 pada Fraktur Osteoporosis,” Cdk, vol. 40, no. 10, pp. 751–755, 2013, [Online]. Available: https://www.researchgate.net/publication/315096955

K. M. Aasarød, M. P. Mosti, M. T. Finstad, A. K. Stunes, R. Fossmark, and U. Syversen, “Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?,” Bone Reports, vol. 14, no. March, pp. 1–6, 2021, doi: 10.1016/j.bonr.2021.101095.

M. S. A. Kawilarang, A. E. Mongan, and M. Memah, “Gambaran kadar serum magnesium pada pasien penyakit ginjal kronik stadium 5 non dialisis di Manado,” J. e-Biomedik, vol. 4, no. 1, pp. 210–217, 2016.

Ż. Ciosek, K. Kot, D. Kosik-Bogacka, N. Łanocha-Arendarczyk, and I. Rotter, “The effects of calcium, magnesium, phosphorus, fluoride, and lead on bone tissue,” Biomolecules, vol. 11, no. 4, 2021, doi: 10.3390/biom11040506.

R. Wildawati, Y. Anggreny, and D. K. Putri, “Determinan Pencegahan Osteoporosis Pada Wanita Menopause,” J. Ners Indones., vol. 10, no. 2, p. 229, 2020, doi: 10.31258/jni.10.2.229-237.